表紙
市場調査レポート

EpiCast Report:糖尿病黄斑浮腫の疫学予測

EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 312372
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
EpiCast Report:糖尿病黄斑浮腫の疫学予測 EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023
出版日: 2014年09月10日 ページ情報: 英文 54 Pages
概要

黄斑浮腫(ME)は、網膜で中心視野を担う、黄斑の肥厚・腫脹(浮腫)が原因で発生します。世界の主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)における糖尿病黄斑浮腫(DME)の発症件数は、2013年の922,492件から、今後10年間で1,238,301件まで、34.2%増加すると予測されています。

当レポートでは、世界の主要7ヶ国における糖尿病黄斑浮腫(DME)について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • 主要5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法 - 糖尿病と診断された患者数
    • 予測の前提条件と手法 - 糖尿病網膜症と診断された患者数
    • 予測の前提条件と手法 - 糖尿病網膜症と診断された患者数のうち、糖尿病黄斑浮腫(DME)と診断された患者数
    • 予測の前提条件と手法 - 網膜静脈分枝閉塞症(BRVO)・網膜中心静脈閉塞症(CRVO)に次ぐ、黄斑浮腫の総患者数
  • 黄斑浮腫の疫学予測
    • 糖尿病網膜症と診断された患者数のうち、DMEと診断された患者数
    • 糖尿病網膜症と診断された患者数のうち、DMEと診断された患者数:年齢別
    • 糖尿病網膜症と診断された患者数のうち、DMEと診断された患者数:性別
    • BRVOに次ぐ、MEの総患者数
    • BRVOに次ぐ、MEの総患者数:年齢別
    • BRVOに次ぐ、MEの総患者数:性別
    • CRVOに次ぐ、MEの総患者数
    • CRVOに次ぐ、MEの総患者数:年齢別
    • CRVOに次ぐ、MEの総患者数:性別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER031-14

Macular edema (ME) occurs due to the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. In ME, fluid and protein deposits collect on or under the macula of the eye, due to a breakdown in the blood-retinal barrier. The occurrence of ME is highly frequent in diabetics and usually manifests itself as diabetic macular edema (DME). DME is often a complication of diabetic retinopathy, and is the most common cause of vision loss in individuals with diabetes, especially if left untreated. The risk for ME is high in patients with retinal vein occlusion (RVO), which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population in the 7MM will increase by 34.2% during the forecast period, from 922,492 cases in 2013 to 1,238,301 cases in 2023. The total prevalent cases of ME following BRVO in the 7MM will increase by 13.7% during the forecast period, from 294,862 cases in 2013 to 335,346 cases in 2023. The total prevalent cases of ME following CRVO in the 7MM will increase by 19.6% during the forecast period, from 114,571 cases in 2013 to 136,973 cases in 2023.

GlobalData's epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across markets.

Scope

  • The Diabetic Macular Edema (DME) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for DME in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME in the diagnosed diabetic retinopathy population and the total prevalent cases of ME following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) segmented by sex and age (20-39 years, 40-59 years, 60-79 years, and =80 years) in these markets.
  • The DME epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global DME market.
  • Quantify patient populations in the global DME market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for DME therapeutics in each of the markets covered.
  • Identify the number of ME cases following BRVO and CRVO.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Diabetes
    • 3.4.4. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Diabetic Retinopathy
    • 3.4.5. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 3.4.6. Forecast Assumptions and Methods - Total Prevalent Cases of ME following BRVO and CRVO
  • 3.5. Epidemiological Forecast for Macular Edema (2013-2023)
    • 3.5.1. Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population
    • 3.5.4. Total Prevalent Cases of ME Following BRVO
    • 3.5.5. Age-Specific Total Prevalent Cases of ME Following BRVO
    • 3.5.6. Sex-Specific Total Prevalent Cases of ME following BRVO
    • 3.5.7. Total Prevalent Cases of ME Following CRVO
    • 3.5.8. Age-Specific Total Prevalent Cases of ME Following CRVO
    • 3.5.9. Sex-Specific Total Prevalent Cases of ME Following CRVO
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors for DME
  • Table 2: Comorbidities for DME
  • Table 3: 7MM, Sources of Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population
  • Table 4: 7MM, Sources of Total Prevalence of ME following BRVO and CRVO
  • Table 5: 7MM, Sources Not Used in Epidemiological Analysis of DME
  • Table 6: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Table 7: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, (Row %), 2013
  • Table 8: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ≥20 Years, N (Row %), 2013
  • Table 9: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Table 10: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, (Row %), 2013
  • Table 11: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ≥20 Years, N (Row %), 2013
  • Table 12: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Table 13: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, (Row %), 2013
  • Table 14: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ≥20 Years, N (Row %), 2013

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, 2013
  • Figure 3: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ≥20 Years, N, 2013
  • Figure 4: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 5: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, 2013
  • Figure 6: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ≥20 Years, N, 2013
  • Figure 7: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 8: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, 2013
  • Figure 9: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ≥20 Years, N, 2013
Back to Top